AnteoTech secures a significant order from the Serum Institute of India and expands its Life Sciences pipeline with new product developments and global partnerships, positioning for accelerated growth in 2026.
Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.
Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.